Series A Financing Company / New Enterprise Associates / Fidelity Biosciences / Notes Guggenheim Securities / Novo A/S / Adaptimmune Editors / Foresite Capital Management / GlaxoSmithKline / Rock Springs Capital / Ridgeback Capital Management / ADAPTIMMUNE LIMITED / OrbiMed Advisors LLC / Immunocore Ltd / Wellington Management Company LLP / Bristol Myers-Squibb / PR Adaptimmune Ltd / /
Country
United States / United Kingdom / /
Currency
USD / / /
Event
Funding / Business Partnership / Employment Change / Company Expansion / /
Facility
University of Oxford / Adaptimmune laboratory / /
IndustryTerm
biotechnology / machinery / healthcare / healthcare team / regarded biotechnology investment groups / cell receptor engineering technology / /
MedicalCondition
ovarian cancer / multiple myeloma / clinical cancer / melanoma / breakthrough cancer / cancer / sarcoma / infectious disease / /
MedicalTreatment
cell therapy / /
Organization
University of Oxford / /
Person
David Mott / Merlin Nexus / James Noble / Peter Thompson / Ali Behbahani / Jonathan Knowles / Select Nexus / Elliott Sigal / / /
Position
Chief Executive Officer / independent industry representative / Chairman / Contact Margaret Henry Head / head of healthcare / Chief Scientific Officer and Executive Vice President / /
PRESS RELEASE – ADAPTIMMUNE LIMITED Adaptimmune secures $104 million in Series A Financing Company will use funding to advance programmes in multiple cancer indications (Oxford, UK and Philadelphia, PA, 25 September 2